BLCO
Bausch + Lomb Corp.

511
Mkt Cap
$5.53B
Volume
401,570.00
52W High
$20.94
52W Low
$10.45
PE Ratio
-20.21
BLCO Fundamentals
Price
$15.63
Prev Close
$15.75
Open
$15.71
50D MA
$14.83
Beta
1.09
Avg. Volume
537,662.62
EPS (Annual)
-$0.9011
P/B
0.86
Rev/Employee
$354,888.89
Loading...
Loading...
News
all
press releases
Activist Investor Turns Up Heat On Cooper, Urges Bausch + Lomb Merger To Boost Returns: Report
Jana Partners is urging Cooper to improve capital use and returns, saying its contact-lens and women’s health units lack strategic fit and drag on performance.
Stocktwits·2d ago
News Placeholder
More News
News Placeholder
BLCO vs. DHR: Which Stock Should Value Investors Buy Now?
BLCO vs. DHR: Which Stock Is the Better Value Option?
Zacks·19d ago
News Placeholder
Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +16.67% and +2.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for July 30th
ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for July 24th
COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.
Zacks·3mo ago
News Placeholder
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty
Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to weigh on sales growth, earnings, and investor sentiment. Brokerage cut its price target to $15 from $24, based on 9.5x its 2026 EBITDA estimate of $1.0 billion.
investing.com·7mo ago
News Placeholder
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Stocktwits·8mo ago
News Placeholder
Bausch & Lomb to shake up contact lenses with deal off the table
Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed...
Yahoo! Finance-YouTube·8mo ago

Latest BLCO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.